Related Experiment Video
Updated: Dec 18, 2025
Generation of 3D Tumor Spheroids for Drug Evaluation Studies
Published on: February 24, 2023
Abstract:
The latest results from the CodeBreak 100 trial evaluating AMG 510 indicate that this first-in-class KRAS inhibitor, having shown promise in non-small cell lung cancer, is modestly active in several other types of solid tumors, including colorectal cancer.
Insights
The CodeBreak 100 trial shows AMG 510, a KRAS inhibitor, is effective in non-small cell lung cancer and other solid tumors. This includes modest activity in colorectal cancer, expanding treatment options.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The CodeBreak 100 trial investigates AMG 510, a novel KRAS inhibitor.
- AMG 510 has demonstrated prior efficacy in non-small cell lung cancer (NSCLC).
Discussion:
- This study evaluates AMG 510's activity across various solid tumor types beyond NSCLC.
- Colorectal cancer is among the solid tumors assessed for AMG 510's therapeutic potential.
Key Insights:
- AMG 510 exhibits modest activity in several solid tumors, including colorectal cancer.
- The findings suggest a broader applicability of KRAS inhibition in oncology.
Outlook:
- Further research is warranted to explore AMG 510's efficacy and safety in diverse solid tumors.
- This could lead to new therapeutic strategies targeting KRAS mutations in various cancers.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
